Allergan's competitors

Allergan's competitors include Bristol-Myers Squibb, Novartis, Roche and XOMA
Add company...
Allergan
Allergan is a global pharmaceutical company.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Novartis
Novartis provides healthcare solutions that address the evolving needs of patients and societies.
Roche
We are the world's number 1 in biotech with 17 biopharmaceuticals on the market.
XOMA
XOMA is a biotechnology company discovering, developing and commercializing antibody-based therapeutics.
Founding Date
Founding Date
1948
Founding Date
1887
Founding Date
1996
Founding Date
1896
Founding Date
1981
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Dublin, IE HQ
Parsippany Troy Hills, US
Locations
New York, US HQ
Hopewell, US
Bi, DE
Devens, US
Mulhuddart, IE
Fort Myers, US
Lawrence Township, US
see more
Locations
Basel, CH HQ
Beijing, CN
Wehr, DE
Tokyo, JP
East Hanover, US
New York, US
Locations
Basel, CH HQ
South San Francisco, US
Locations
Emeryville, US HQ
Employees
Employees
16,700 46% decrease
Employees
25,000
Employees
121,000 2% increase
Employees
94,052
Employees
18 78% decrease
Valuation ($)
Valuation ($)
59.3 b
Valuation ($)
99.9 b
Valuation ($)
175.5 b
Valuation ($)
N/A
Valuation ($)
275.1 m
Facebook followers
Facebook followers
203
Facebook followers
120.2 k
Facebook followers
277.6 k
Facebook followers
75.9 k
Facebook followers
N/A
Twitter followers
Twitter followers
22 k
Twitter followers
117.7 k
Twitter followers
229.5 k
Twitter followers
172.6 k
Twitter followers
188

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$19.4b (FY, 2016)
Revenue (est.)
$48.5b (FY, 2016)
Revenue (est.)
Fr.48.1b (FY, 2015)
Revenue (est.)
$5.6m (FY, 2016)
Cost of goods
Cost of goods
N/A
Cost of goods
$4.9b (FY, 2016)
Cost of goods
$17.5b (FY, 2016)
Cost of goods
Fr.15.5b (FY, 2015)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$14.5b (FY, 2016)
Gross profit
$31b (FY, 2016)
Gross profit
Fr.32.7b (FY, 2015)
Gross profit
N/A
Net income
Net income
N/A
Net income
$4.5b (FY, 2016)
Net income
$6.7b (FY, 2016)
Net income
Fr.9.1b (FY, 2015)
Net income
($53.5m) (FY, 2016)

Operating

Major Approvals (US, EU, JP)
Major Approvals (US, EU, JP)
N/A
Major Approvals (US, EU, JP)
N/A
Major Approvals (US, EU, JP)
16 (Y, 2016)
Major Approvals (US, EU, JP)
12 (Y, 2016)
Major Approvals (US, EU, JP)
N/A
Phase III Trials
Phase III Trials
N/A
Phase III Trials
8 (Y, 2016)
Phase III Trials
29 (Y, 2016)
Phase III Trials
N/A
Phase III Trials
N/A
US FDA Breakthrough Therapy Designations
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
5 (Y, 2016)
US FDA Breakthrough Therapy Designations
5 (Y, 2016)
US FDA Breakthrough Therapy Designations
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles